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Abstract
The purpose of this project is to develop a protocol for analyzing relevant metabolites in mouse
urine using Nuclear Magnetic Resonance (NMR) Spectroscopy and to communicate these
findings, with background information, in this paper. By comparison of the concentrations of
these metabolites, the effects of HT1 and NTBC on metabolism can be established. A murine
model of HT1 is being used and four types of urine analyzed: NTBC treated HT1 mice, untreated
HT1 mice, NTBC treated healthy mice, and untreated healthy mice. Samples of known
metabolites at known concentrations were prepared for both NMR and MS, and spectra were
obtained and processed. The limits of quantification were determined for each. Characteristics of
individual compounds are influenced by the presence of other components in the mixture, so a
standard mixture of these metabolites was prepared for NMR to observe the effect of shielding.
Fresh urine will be collected from all four mouse groups and the NMR and MS studies repeated
with those samples. Collected spectra will then be processed and differences in concentrations of
individual metabolites within the urine determined. Eight key metabolites of the tyrosine
catabolic pathway have been identified, a database of metabolite spectra has been drafted, and a
protocol for NMR and MS analysis of neurotransmitters and amino acids in mixtures developed.
Problems encountered in determining concentrations included lack of sensitivity and overlap
between peaks in the NMR spectrum. This was somewhat overcome by using multiple methods
of analysis—NMR and LC-MS—and analyzing data with both VNMRJ® and MestreNova®
software. 2D NMR experiments will be used in future work to minimize peak overlap.
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Introduction
Every living creature is made up of a complex array of proteins, enzymes, lipids, and small
organic molecules, called metabolites, which are coded for in the genome. The genome consists
of all the heritable information of an organism, recorded in genes, the coding regions of
deoxyribonucleic acid (DNA). Deoxyribo- refers to the ribose sugar, which lacks a hydroxyl
group in the 2’ position, and nucleic acid refers to the nucleotide bound to the backbone of the
DNA molecule at the 1’ position. Genes are expressed by being transcribed from nucleotide
triplet codons into messenger ribonucleic acid (mRNA), further processed and spliced, and
translated into amino acid polymers, called proteins. Gene expression gives rise to all traits and
processes associated with sustaining life, and heritable alterations in the DNA sequence are
called mutations. Depending on the location and type, mutations can be innocuous, like those
which occur in the non-coding regions of DNA, or can lead to debilitating genetic diseases
(Alberts, 2014). Genes are made up of a sequence of purine—adenine and guanine—and
pyrimidine—thymine and cytosine—molecules, called nucleotides. Nucleotides are planar,
aromatic compounds and are bound together in a polymer with a sugar-phosphate backbone. The
structures of the purine and pyrimidine bases, as well as their connectivity in the DNA polymer,
is shown in Figure 1.
DNA forms a double helix of two complementary and antiparallel strands. Between the
individual strands, weak electrostatic interactions, called hydrogen bonds, allow for pairing of
complementary nucleotides. The cumulative effect of these many weak interactions is powerful
enough to hold the strands together and prevent degradation of the DNA by endonucleases, but
not so strong as to prevent the separation of strands by enzymes for replication and transcription.
The DNA is then wound around histone proteins and further supercoiled to form chromosomes.
DNA is found in the nucleus of eukaryotic cells as
chromosomes, which separate during replication, the
biological process by which identical copies of DNA are
produced (Nelson, 2013).

Metabolomics
Genes are relatively small sections of the genome which
code for proteins and enzymes or simply serve a structural
(non-coding) function within the DNA. When genes are
mutated, they may give rise to dysfunctional proteins and
enzymes, which in turn effect the metabolism of the
organism. Nearly every reaction which occurs within an
organism requires an enzymatic catalyst. To maintain
Figure 1. The structure of DNA
homeostasis all reaction pathways are interdependent and,
and RNA nucleotide bases.
whether biosynthetic or degradative, if nonfunctional will
cause accumulation of intermediate compounds. The metabolome of an organism, like the
genome, consists of the sum of metabolites in an organism at a given point in time.
Metabolomics is the study of changes in concentration of metabolites within an organism,
usually associated with disease pathogenesis (Nelson, 2013). By studying changes in metabolite
concentration over time, scientists can better understand the biochemical foundations of disease
and develop novel treatments and improved methods for early detection, diagnosis, and
monitoring. These methods allow for better treatment and are already being applied to many

genetic disorders as well as several types of cancer (Alberts, 2014). Hereditary Tyrosinemia
Type 1, or HT1 for short, is one such genetic disease and is the subject of this paper.

Hereditary Tyrosinemia Type 1
HT1 is a genetic disease of autosomal recessive inheritance. It is the result of a mutation or set of
mutations in the fah gene which codes for the fumarylacetoacetate hydrolase (FAH) enzyme
product, producing a nonfunctional enzyme in the final step of the degradation of tyrosine, an
essential amino acid (McKusick, 2005). Without FAH activity, a toxic accumulation of
untransformed metabolites earlier in the pathway occurs in every cell of the patient and disease
symptoms develop (Grompe, 1994). Maleylacetoacetate (MAA), fumarylacetoacetate (FAA),
succinylacetone (SA), and succinylacetoacetate (SAA) accumulate and are believed to be
responsible for the severe organ damage resulting from HT1 (Al-Dirbashi 2008; Barnby, 2014).
If minimal function is retained in the FAH enzyme the disease is less severe and referred to as
chronic HT1, whereas complete loss-of-function results in acute HT1. Without early diagnosis
and treatment, acute HT1 often leads to death in early infancy, while proper treatment of chronic
HT1 can provide a relatively normal life for patients (Karnik, 2004). The incidence of HT1 is
approximately two cases for every 100,000 births, with much higher rates in the Saguenay-Lac
St Jean region of Canada (Grompe, 1994). This is considered to be an underestimation of true
incidences of HT1 because death in early infancy is often labelled as Sudden Infant Death
Syndrome (SIDS), and without genetic testing it would not be known if it was due to HT1
(Barnby, 2014).
The symptoms of HT1 vary depending on the exact mutations and degree to which FAH is
dysfunctional. As seen in Figure 3, the metabolic pathway of tyrosine is incredibly complex.
This
complexity, and
the extremely
low
concentrations
at which
individual
metabolites
exist, make it
challenging to
identify which
metabolites are
accumulating
and responsible
for the disease
symptoms.
Current
diagnosis is
based on
Figure 2. The biochemical pathway of tyrosine metabolism (Kanehisa
genetic testing
Laboratories, n.d.).
and evaluation
of SA
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concentration in blood samples while treatment is primarily symptom-based and tailored to the
individual (Bliksrud, 2005).

Symptoms
Individuals with HT1 must undergo frequent screening to manage the disease as many factors
must be regularly monitored, including concentrations in the blood and plasma of SA, MAA,
FAA, SAA, tyrosine, and phenylalanine, as well as the condition of the liver for nodal
abnormalities (Barnby, 2014). Symptoms associated with HT1 include cirrhosis of the liver,
hypophosphatemic rickets, liver failure, renal tubular defects, kidney damage, progressive liver
disease, neurological crises, respiratory distress, reduced cognitive function, ascites, and
coagulopathy (Lindblad, 1977; Bliksrud et al., 2005; Barnby, 2014). Not all symptoms are
experienced by all patients, and both the age of onset and degree to which the disease presents in
a patient is variable between individuals and over time. Most patients show symptoms in early
infancy, others later in infancy.
In the most acute form, patients experience severe liver failure within weeks of birth. In chronic
HT1, rickets is the major symptom and untreated patients typically die from cirrhosis of the liver
or hepatocellular carcinoma early in life (Bliksrud et al., 2005). It is believed that MAA and
FAA accumulation is the major cause of liver disease in HT1 patients as these molecules cause
hepatocyte injury at high concentrations. SA is an inhibitor in the pathway of heme synthesis and
causes neurotoxicity following a similar pathway to aminolevulinic acid dehydratase (ALAD)
deficiency porphyria causing paralysis and respiratory arrest (Barnby 2014).

Diagnosis
In the past, diagnosis of HT1 and the related genetic disorders of tyrosine catabolism was based
on the presence of indicator molecules in the urine. A tissue deficiency of FAH protein as well as
the presence of SA in the urine indicated that the patient had HT1. Increased levels of αfetoprotein, tyrosine, methionine, proline, and alanine in the plasma served to increase
confidence of diagnosis, as well as several indicators in the urine (Karnik, 2004). Current
diagnosis of HT1 measures the presence of multiple disease markers in blood spot specimens
using tandem mass spectrometry, a quantitative device used in prenatal screening of many
diseases and disorders. Though the measurement of SA concentration is also used, tyrosine
measurements have been shown to be relatively inaccurate for diagnosis and are not considered.
With mandatory infant screening in most states, early diagnosis of HT1 greatly enhances the life
expectancy of HT1 patients as medical interventions can take place prior to the onset of
symptoms (Barnby, 2014).

Treatment
Today, treatment of HT1 is complex and primarily symptom-based, as little is known about the
precise metabolic changes which occur in the disease pathogenesis. A team of medical
professionals from diverse specialties are needed to ensure the most positive patient outcomes.
These professionals include a dietician, medical geneticist, psychologist, school nurse liaison,
and an on-call advanced practice nurse (Barnby, 2014). Patients are encouraged to minimize
their consumption of protein and instructed to never skip meals or go long periods without
eating, since the breakdown of body proteins during fasting will increase the level of circulating
tyrosine and increase the severity of disease symptoms. The only available medication is
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nitisinone, known by its trade name Orfadin®, which slows the onset and development of
disease symptoms. Nitisinone will be referred to as NTBC in this paper, an abbreviation of the
full chemical name, 2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione (“Nitisinone,”
n.d.).
NTBC acts by shifting the metabolic pathway for the catabolism of tyrosine by inhibition of the
enzyme Hydroxyphenyl-Pyruvate Dioxygenase (HPPD) upstream in the tyrosine pathway to
FAH. HPPD is inhibited by the binding of NTBC. The natural ligand of HPPD is 4hydroxyphenylpyruvate (4-HPP), which binds to the protein transiently as it undergoes a
chemical transformation called decarboxylation to form homogentisate, the accumulating
metabolite in (Raspail et al., 2011). When NTBC binds, however, the interaction inhibits protein
function by permanently binding to the protein binding site and not allowing 4-HPP to bind. As
seen in Figure 4, NTBC forms a secure attachment to the protein as many forces interact to keep
it in place (Brownlee, n.d.). The resulting change in metabolism gives significantly less severe
symptoms which resemble another genetic disease of the tyrosine pathway, called
phenylketonuria (Kester, 2012).
Early diagnosis, followed by dietary restrictions
and treatment with NTBC, is of critical
importance to prevent excessive liver and
kidney damage due to prolonged exposure to
toxic metabolites. Patients taking NTBC still
must maintain a low-tyrosine and lowphenylalanine diet,and are at significantly
higher risk of hepatocellular carcinoma than the
general population (Kester, 2012). A common
side effect of NTBC is corneal opacities, spots
in the vision due to drug interactions with
tyrosine. For this reason, it is important that
patients taking this drug carefully follow
dietary guidelines and are regularly screened
for cancer (Barnby, 2014).
Figure 3. The structure of NTBC located at its
binding site within the protein.
HT1 is a complex disease, with no effective
treatment available. Depending on the age at which the disease presents and the severity of
symptoms, patients may have little chance of survival and die before age two of liver failure and
uncontrollable bleeding, hepatocellular carcinoma, or porphyria-like syndrome with respiratory
failure (Karnik, 2004). NTBC is only effective in slowing the rate of the disease progression, not
in reversing the damage done to the liver, kidney, and nervous system. With further study of the
HT1 pathway, a better understanding of the metabolic changes occurring could lead to
development of a more effective treatment plan. Instrumentation such as NMR allows for the
evaluation of key metabolites at low concentrations to determine which metabolic
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Nuclear Magnetic Resonance Spectroscopy
Nuclear Magnetic Resonance (NMR) Spectroscopy is one of the most common analytical tools
in chemistry. It is used for elucidating chemical structures of novel compounds, verification of
known compounds, quality control, and quantifying components in mixtures, as well as having
many applications in physical and polymer chemistry. With experience, the structure of a
molecule can be determined by analysis of resonance peak patterns, chemical shift, and
resonance fine structure, typically in conjunction with other analytical tools (Crews,1998). NMR
works by inducing a resonance transition in nuclei and measuring the resulting absorption
spectra and gives information about the number of magnetically distinct nuclei in a molecule or
mixture. It is most often used for detection of proton (1H NMR) and carbon (13C NMR) nuclei.
Two-dimensional NMR gives further information about connectivity within molecular structures
by showing coupling patterns between nuclei at certain distances apart and is also used to
separate overlapping peaks in one-dimensional NMR (Pavia, 2001).

Theory
NMR works by detecting a property of atomic nuclei with odd-atomic mass and odd-atomic
number, odd-atomic mass and even-atomic number, or even-atomic mass and odd-atomic
number, called spin. Spin is a form of angular momentum which is intrinsic to electrons and to
those nuclei which meet the above criteria, called spin-½ nuclei. The spinning charged nucleus
produces its own magnetic field, and the NMR instrument contains a powerful cryomagnet
which provides an external magnetic field that aligns the axes of the spinning nuclei by inducing
an opposed magnetic field in them (Pavia, 2001).
When a radio-frequency (RF) pulse is emitted, the nuclei absorb energy and, due to spin, precess
around an axis in a motion like that of a spinning top. A complex, time-domain signal, called
Free Induction Decay (FID), is detected. This signal decays with time as the nuclei lose energy.
The FID is converted to the frequency domain by the Fourier transform, which is a mathematical
transform that decomposes a time-dependent signal function into its constituent frequencies, as
seen in Figure 4 (Pavia, 2001). In the figure, the FIDs on the left are time-dependent and, after
being transformed, give distinct peaks
in the frequency domain as seen on
the right. This signal, in units of Hz, is
further processed by dividing it by the
spectrometer frequency, in MHz. This
gives the NMR spectrum units of parts
per million (ppm), which is the unit
NMR peak positions are reported in.
This is done so that NMR values are
standardized and therefore not
dependent on the frequency of the
Figure 4. Three FIDs and their respective Fourier
spectrometer the sample is run on.
Transforms (Edwards, 2008).
The characteristic ppm value or values for a molecule are referred to as the chemical shift values.
Chemical shift is dependent on the chemical environment of the nucleus and is influenced by the
electronic structure of the atom and its attachment within the molecule. Differences in resonance
frequencies between nuclei are sufficiently small that measurements must be made with an
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internal standard. Trimethylsilane, (CH3)4Si, (TMS) is often used as an internal standard in NMR
experiments and will be used in the experiments described in this paper. This compound is used
in 1H NMR because the protons of its four methyl groups are significantly shielded and serve as
a “zero” for the spectrum. In this way, NMR spectra are further standardized (Silverstein, 2015).
The NMR spectrometer used in the experiments detailed in this paper is shown in Figure 5. The
instrument works by producing a powerful, microsecond pulse of energy that excites all the
magnetically-active nuclei within the sample at once in the presence of a strong magnetic field
(Crews, 1998). This is what produces the FID, as
mentioned above. Since all resonance frequencies of the
excited nuclei are included in this signal, the Fourier
Transform is necessary to separate them into individual
peaks.
One advantage of pulsed FT-NMR is that with fast
computing, many FIDs can be obtained and averaged by
running multiple scans. This makes it easy to decrease
the noise—random electronic signals that create
noticeable changes in the baseline of the spectrum—by
simply increasing the number of scans so that it cancels
out of the spectrum as much as possible through
averaging (Pavia, 2001). The components of an NMR
capable of producing high-quality spectra are as follows:
a cryomagnet which produces a magnetic field of
constant orientation and strength, an RF transmitter for
electromagnetic radiation pulses, a sensitive RF receiver
to detect weak signals produced by resonating nuclei, a
computer for controlled delivery of pulse sequences
which can store resonance signals, and a recorder with a
digital plotter or similar software for output of the
spectra once obtained (Crews, 1998).

Figure 5. Varian® Unity INOVATM
500 MHz NMR spectrometer
located in the UAH Materials
Science Building.

Liquid-Chromatography-Mass Spectrometry
It is often useful to separate chemicals in a mixture based on physical or chemical properties, and
to determine their mass or mass-to-charge (m/z) ratio. Liquid Chromatography-Mass
Spectrometry is an analytical chemistry tool used to do both at the same time. Liquid
Chromatography, especially High-Performance Liquid Chromatography (HPLC), is used in
chemical laboratories to separate individual components of a mixture using a solvent system
which takes advantage of electronegativity differences of compounds within a mixture. Mass
spectrometry (MS) is a highly accurate balance used for measuring molecular masses.

Theory
Liquid Chromatography, the first phase through which a sample passes in LC-MS, separates ions
or compounds based on their chemical properties as they are dissolved in a solvent or solvent
system. LC is used for separation, identification, and quantification of mixture components based
on how they interact with the mobile and stationary phases. The chromatogram mixes and
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delivers the solvent mobile phase and sample simultaneously via a high-pressure pump onto the
column, and the components are passed through the column to a detector. As the mixture
components in the sample are eluted off the column, they induce a change in conductivity which
is detected and recorded in a data system, or passed on to another analytical tool, such as a mass
spectrometer. Separation occurs as compounds are differentially retained on the column (Snyder,
2010).
A mass spectrometer consists of an inlet stream, often paired directly with a liquid or gas
chromatogram, a gaseous ion source for sample ionization, a mass analyzer, and detector. The
system is under vacuum and connected to a computer for data handling.
Various MS ionization methods exist including electron impact (EI), electrospray ionization
(ESI), atmospheric pressure chemical ionization (APCI), and matrix-assisted laser desorption
ionization (MALDI). EI is the most commonly used method for molecular ionization and was
utilized in the earliest mass spectrometers. A stream of electrons is ejected from a filament and
collide with the analyte molecules at a right angle to produce positive molecular radical ions of
the analyte molecule M. This ionization technique allows for less control of ion formation than
chemical ionization since only positive ions are produced (Futrell, 1985). ESI loads compounds
with charge via an electric field at the tip of the sample loading nozzle as the analyte is
introduced into the chamber. Solvent evaporation occurs and reduces the droplet size until the
charges at the droplet surface reach the Rayleigh limit and induce Coulombic fission and the
production of charged progeny droplets (Banerjee, 2012). This ionization technique is a form of
soft ionization which does not result in decomposition of the species of interest and is therefore
useful for proteomics applications as the mass of a large, intact chemical species can be
determined. APCI utilizes gas-phase ion-molecule reactions at approximately 1 atm to produce
primary ions on a solvent spray, without decomposition of the sample. This method is
predominately utilized for lower-molecular weight species and those which are less thermally
stable (MDS SCIEX, 2002). MALDI was developed for studying biological and synthetic
macromolecules and is a soft ionization method which preserves an intact analyte. Since direct
irradiation of the analyte by a laser pulse would result in structural decomposition, a matrix is
used to absorb the energy of the laser beam and transfer it to the analyte for ionization. MALDI
is coupled with mass-analyzers which allow for high-mass species like time-of-flight (Caprioli,
1997).
Common MS mass analyzers include quadrupole mass analyzer (QMA), time-of-flight (TOF),
and Orbitrap. The QMA setup consists of four rods mounted parallel to one another and
equidistant to form a square with a detector located behind the rods relative to the incident ion
beam. A direct current (DC) voltage is supplied to the rods and modified by a radiofrequency
voltage. This provides a “filter” for ions as only those with a specific mass-per-charge ratio will
travel to the end of the quadrupole and hit the detector. Ions which do not meet the precise m/z
criteria will follow an erratic pathway and strike the quadrupole or miss the detector entirely. By
altering the combination of DC voltage and modified voltage at a constant ratio, different m/z
values can be scanned so that entire mass range is detected (Silverstein, 2015). The advantages
of the quadrupole include low cost and a wide mass range, while low resolution and moderately
low sensitivity make the quadrupole less than ideal for mixtures with similar masses (Dawson,
1976). TOF is typically paired with MALDI and separates ions based on flight time in a drift
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tube after laser excitation. The time-of-flight is used to determine the mass-to-charge ratio using
𝑚

the following equation: 𝑡 = 𝑘√ 𝑞 , where k is a constant which incorporates accelerating voltage
and distance of flight tube (Verbueken, 1988). The Orbitrap mass analyzer is an ion trap
consisting of an electrode around which ions are trapped. Electrostatic attraction is compensated
by centrifugal force arising from the initial velocity of the ions, and the ions oscillate axially
across the trap at a frequency proportional to the square root of the charge-to-mass ratio. The
𝑘

axial oscillation frequency follows the formula 𝜔 = √𝑚/𝑧 , where omega is the oscillation
frequency, k is the instrumental constant and m/z the mass-to-charge ratio of the molecular
species. The resulting signal is converted from the time domain of individual ions to the
frequency domain for individual frequencies of ions with a Fourier transform. The Orbitrap gives
very high resolution, which is useful for experiments requiring a high level of mass accuracy
(CHROMacademy, n.d.).
The spectrum obtained by mass spectrometry is a series of vertical lines which correspond to
charged species separated by m/z and plotted with respect to percent relative abundance. An
electrospray ionization mass spectrum of diphenylacetic acid can be seen in Figure 8 (Smith,
1988).

Figure 6. Example ESI negative mass spectrum. Each line represents a specific m/z of a
molecular fragment, where relative abundance is given in proportion to the tallest peak.
MS has several advantages over NMR. MS tends to be more sensitive, and experiments often
have shorter run times. MS can be used to determine the molecular formula of novel compounds
based on fragmentation patterns and is very useful in complex mixture analysis for determining
components based on their molecular ion peaks. Additionally, targeted analysis to determine the
presence and quantify specific components is possible. In both NMR and MS, untargeted
analysis to observe changes can be performed and evaluated statistically. Both NMR and MS
serve to support each other, and neither can replace the other.
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Workflow
Samples are prepared either from aqueous solutions or powdered solids and suspended in a polar
solvent such as methanol. The samples ran in the experiments reported in this paper were ran in a
methanol-water solvent with a 1:1 ratio. Initially, each metabolite was prepared as a standard
solution with a concentration of 500 μg/ml and diluted down to 1.95 μg/ml via seven dilutions by
half. These dilution series were run on the available Thermo Scientific Orbitrap XL® LC-MS to
determine the minimum concentration at which the molecular ion peaks were clearly detectable.

Summary of Previous Work
Four groups of mice have been raised and tested for social and cognitive function. Mice with
HT1, taking NTBC and not taking NTBC, and healthy mice, taking NTBC and not taking
NTBC. Independently of NTBC treatment, mice with HT1 showed reduced learning and ability
to adapt (Hillgartner, 2016; Moore, 2017). Urine from these mice was collected and analyzed
using 2D heteronuclear single quantum coherence (HSQC) NMR spectroscopy. Twenty-one
metabolites were identified, and a database drafted of metabolites that can be found in urine and
metabolites that are unique or have altered concentrations in the urine of diseased mice. Eight
key metabolites in the HT1 mouse urine have been identified. Current work is in developing a
metabolomics protocol for analyzing the mouse urine components using NMR and LC-MS. The
difficulty in this project arises from the complexity of the mixture being analyzed. Metabolomics
databases contain approximately 75,000 different metabolites in the urine and identifying
individual components requires careful experimental design and execution (“Human
Metabolome Database,” 2017). Beyond this, the metabolites are in an aqueous solution, which
by itself is a challenge due to concentration changes with evaporation or sublimation. Further
complications arise from the inherently low concentrations of the individual components and the
detection limits of NMR and LC-MS, and the fact that identification of compounds in NMR is
based on chemical shift and peak patterns which change based on concentration, pH, and the
presence of other compounds. Since these criteria alter the identifying structures in the spectra, it
is vital that their influence be understood and accounted for.
The purpose of this project is to analyze the urine of mice with and without HT1 and on and off
the drug NTBC to determine changes in neurotransmitter or metabolite levels related to
mechanism of action of this drug. Eventually this will lead to a better understanding of the
disease pathogenesis and why the observed phenotypes are expressed. The scope of this project
is quite focused—metabolomic analysis of urine of mice with a rare genetic disorder—but
important for the field of metabolomics and those with the disease.

Chapter 1: Chemical Methods
Sample Preparation
The eight metabolites of interest were prepared and analyzed individually using NMR. Each was
prepared from a research-grade crystalline powder obtained from Sigma-Aldrich or Acros
Organics first at the limit of solubility, and with decreasing concentrations to determine limits of
detection.
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To observe interactions between components, a 1-2 mM mixture of the eight metabolites was
prepared using a phosphate buffer at pH 7. Multiple experiments were run on both the 3 mm and
5 mm NMR probe to establish a standard spectrum. The shift of the peaks was compared with
the individual spectra, and despite a certain amount of peak overlap, individual peaks for
quantitation were established for each compound.
This mixture, referred to as “artificial mouse urine,” was compared to real mouse urine and it
was observed that the chemical shift of many compounds was similar, but with some shift in the
real mouse urine due to the many components in mouse urine and differing pH. As a result,
several experiments were run to determine the influence of spiking the artificial mouse urine
with a higher concentration of an individual metabolite.
For mouse urine samples, the urine collected from several different mice within the same group
or from one mouse over the course of several days were pooled to obtain a high enough volume
for NMR and DSS/D2O added to establish a reference peak.

NMR Experiments
The NMR instrument used in the experiments detailed in this paper is a Varian® INOVA®
Pulsed Fourier Transform (Pulsed FT-NMR) instrument with an operating frequency of 500
MHz located in the Alabama High Field NMR Center on UAH campus. Two types of NMR
experiments were followed: (H)PRESAT experiments were performed for single-component
samples to produce one-dimensional NMR spectra with suppression of water signal and proton
presaturation, and a one-dimensional NMR pulse sequence called PSYCHE for mixtures and
mouse urine. Additionally, a small number of two-dimensional spectra— Correlation
Spectroscopy (COSY) and Heteronuclear Single-Quantum Coherence (HSQC) for further
differentiation in peak assignment—were obtained to separate overlapping peaks. Characteristic
peak patterns for individual compounds were established and a consistent NMR pulse sequence
utilized when collecting 1H NMR (H)PRESAT spectra. Relevant instrument specifications
include resistance below 50 Ω, a lock between 40 and 60, 10% D2O, and 8 scans.
NMR experiments utilized:

Workflow
First, a new 3mm or 5mm glass capillary tube with cap is obtained depending on the volume and
dilution of sample needed. If a 3mm capillary is used, the probe of the NMR must be swapped
out since 5mm capillaries are typically used. If the sample is a powdered solid, it is mixed and
D2O or another deuterated solvent is added to produce a standard concentration of deuterium. In
some cases, the sample is dissolved directly in the deuterated solvent, in others a phosphate
buffer or other non-NMR-active buffer is used, and the deuterated solvent is added so that it
constitutes 10% or more of the sample volume. The sample is pipetted into the capillary and the
tube capped and labelled.
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To run the sample, the capillary is first inserted into a spinner and the depth
gauge used to ensure that it is at the proper depth for exposure to the RF
pulses, as seen in Figure 8. After removal from the depth gauge, the blank
capillary tube and spinner are ejected and removed from the NMR, and the
sample, inside the spinner, is placed in the sample port located on top of the
instrument. The spinner’s position is maintained by a jet of pressurized air
until it is inserted electronically into the spectrometer. Following insertion,
the NMR software is used to setup the instrument. For 1H NMR
experiments, the PROTON tab is selected, followed by setup hardware. The
probe is then manually tuned so that the resistance is below 50 ohms. After
this, the instrument is locked on D2O and, if necessary, the power, gain,
phase, and z0 are adjusted until the lock scan reads between 40 and 60. After
this the instrument is shimmed to precisely align the magnetic field with the
sample. This is done by typing gmapsys into the command window of the
software, selecting an appropriate load map, and running several preliminary
FIDs. The desired pulse sequences are loaded and the sampling parameters,
Figure 8: NMR
including number of scans, relaxation delay, acquisition time, operating
temperature, solvent system, and presaturation delay. Once ready, the sample sample in depth
gauge and
file is saved and the experiment submitted (Agilent Technologies, 2014).
spinner.
After collecting spectra, they must be processed and interpreted to adjust the
baseline, align the TMS signal with 0 ppm, and suppress the water and TMS signals. An NMR
spectrum, obtained and processed by the author, is shown in Figure 7.

Figure 10: Example 1H NMR
spectrum of 3,5-dimethylbenzoic acid
(Reusch, 2013).

Processing NMR Spectra
MestreNova
When quantifying components using NMR spectra it is imperative that the protocol for
processing the spectra is consistent for each component and correctly developed and followed
throughout given the experimental parameters. Accurate data analysis is crucial in quantification
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of samples to yield significant results, especially at the low concentrations of individual
components observed in urine.
For quantification of individual compounds in MestreNova, first the structure of the compound is
drawn using ChemSketch or Accelrys software. The structure is then pasted onto the NMR
spectrum of interest and the protons assigned using auto assignment. This assignment is checked
manually to verify that the peaks are labelled correspondingly to the correct proton. A 5% drift
correction is applied, and reference peaks set (TMS to 0 ppm and H2O to 4.78 ppm). The TMS
and H2O signals are then suppressed, and a Bernstein polynomial baseline correction applied.
Manual phasing is performed as needed to further smooth the baseline and correct for peaks with
asymmetric bases. For quantification, the following steps are followed: The Analysis tab is
selected, then Multiplet analysis, Manual assignment of number of protons for each peak is
performed by the user, the peak of interest is selected, qNMR inclusion selected, the TMS box
unchecked for correct concentration averaging.
For simple mixture analysis (SMA) using MestreNova, a more complex procedure is followed to
build a library of individual components and from there analyze mixtures to evaluate changes in
chemical shift due to interactions between components. In the following procedure, the most
recently released version of Mestrelab is used (MestReNova Mestrelab Research Chemistry
Software Solutions © Mestrelab Research S.L. Released: 2018-01-03 Version: 12.0.1-20560).
The process to quantify components in a simple mixture using NMR is outlined.
First, the file containing the spectrum of interest is opened in MestreNova, and the most recently
acquired (H)PRESAT experiment (experiment with highest value) selected and the fid file
opened. Once opened, the spectrum should resemble the one shown in Figure 11 below.

Figure 11. Example spectrum opened in MestreNova for SMA analysis.
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Once opened, the spectrum is processed and drift correction of 5% applied. Using the reference
tab, the DSS or TMS peak (peak with lowest shift) is selected and assigned a shift of 0 ppm, as in
Figure 12.

Figure 12. Assignment of reference peak for NMR spectrum for MestreNova SMA.
The spectrum is zoomed to the relevant region of the spectrum, for this procedure between -0.5
ppm and 10.5 ppm consistently. The water signal appearing at approximately 4.77 ppm is then
suppressed and the selectivity parameter set to 12. After this, manual phasing is performed on the
spectrum to flatten the baseline, as seen in Figure 13. While phasing, it is necessary to
exaggerate the peak intensities by scrolling up with the mouse so that the baseline is more clearly
visualized.

Figure 13. Manual phasing of spectrum in MestreNova for SMA.
An automatic baseline correction is applied using the Whittaker smoother, and the structure of
the compound (created using ChemSketch) pasted within MestreLab. After this, the
“assignments” tab is selected and “auto assignment chosen. At this point, the spectrum should
look similar the one of 5-hydroxyindole-3-acetic acid shown in Figure 14, and the proton
assignments should be carefully checked to ensure that correct assignments were given. The
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quantitation tab is then selected, and the simple mixture edited to add the new compound by
name to the mixture. The molecular weight and type of component (reference or compound) is
given and “peaks” is selected as the integration method. For the formula, the current spectrum is
selected, and under the options tab the following are selected before adding the compound to the
mixture: check relative areas ratio and verbose pattern recognition algorithm. The green play
button is selected to analyze the mixture and results produced including multiplet determination,
enumeration of prescribed equations, and notification of inconsistencies (Mestrelab Research,
2017).

Figure 14. Structure of 5-hydroxyindole-3-acetic acid pasted onto spectrum in MestreNova
for SMA showing automatic proton assignment

Chapter 2: Biological Methods
Social and Cognitive Tests
Barnes Maze
The Barnes Maze tests for social and cognitive function based on behavior and is shown in the
figure below. Mice are introduced to a horizontal circular maze for which there is only one escape
hole. The path the mouse takes is monitored and recorded to observe the amount of time required
to find the exit and determine if the mouse searched for an exit or searched randomly. This shows
cognitive function in mice since a healthy mouse will strategically circumnavigate the maze to
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find the exit, whereas a mouse with decreased cognitive function will search at random.

Figure 15. Barnes maze results showing that mice with HT1 (Fahmut) randomly search for the
probe hole to escape the maze, and do not search systematically, demonstrating decreased neural
function (Hillgartner, 2016).

Urine Collection
Experimental verification using NMR was performed to determine that there is no significant
distortion or influence in NMR spectra obtained due to using saran wrap for urine collection. For
all mouse urine collected prior to November 2017, refer to Mouse urine collection using clear
plastic wrap, B.T. Kurien and R.H. Scofield for protocol.
For all further collections, a cage was constructed by removing approximately the last 3 inches of
a clear plastic mouse cage using a saw and securing metal mesh on the bottom of it. When the
top of the cage was placed on the bottom of the cage, the mesh allowed for a raised platform for
the mice to walk on, below which the urine was collected on clear plastic wrap (Saran wrap).
The plastic wrap was placed below the metal mesh and the mice were left to urinate for no more
than 2.5 hours. The mesh both prevented fecal contamination by the mice and prevented them
from walking or rolling in the urine so that it was kept untainted for use in experiments.

Chapter 3: Data
The data collected consisted of NMR spectra of individual compounds, mixtures of compounds
of interest to mimic mouse urine in terms of concentration and pH, and spectra of mouse urine.
Additionally, spectra of artificial mouse urine spiked with pure individual compounds of interest
to observe concentration-dependent changes in shift were performed.
Eight key metabolites were prepared and analyzed individually using a 500 MHz Varian NMR
and Thermo Scientific HPLC LC-MS. NMR spectra for individual compounds were superimposed
using MestReNova software and the stacked spectra were compared with a spectrum of synthetic
mouse urine. The spectra of individual components are shown in the appendix. Identifying peaks
were determined for individual compounds for quantitation and the concentration limits of
detection determined for individual compounds. In the figure below (Figure 16), it can be observed
that though the metabolites of interest produce peaks which are clustered in similar regions of the
spectrum, it is still possible to identify individual compounds as there is no compound for which
all peaks overlap.
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Figure 16. Stacked one-dimensional 1H NMR spectra of eight key metabolites. This shows that it
is possible to perform quantitation on individual components within the mixture since discrete
peaks exist for each.
The artificial mouse urine mixture was then compared with the 1H NMR spectrum of the mouse
urine, as shown in 17.
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Figure 17: Comparison between stacked individual component 1H NMR spectra of artificial
mouse urine mixture and mixture.
Above is the NMR stack of synthetic mouse urine showing individual components, below is the
artificial mouse urine mixture. Chemical interactions between components in the mixture result
in different peak patterns than for the individual components. This helps in identifying peaks
which are shifted in the urine sample due to similar shielding effects.
The artificial mouse urine was evaluated to establish that quantitation could be performed on the
mixture, with 28 unique peaks identified and quantified, as shown in the table below. This
analysis was performed using MestreNova and the previously collected and analyzed spectra of
individual mouse urine components shown in Figures 21-29 in the appendix. Peaks were
manually picked and assigned their corresponding compound and number of nuclei based on
their positions (ppm) and multiplicity.

Eason 17

Table 1. MestreNova data output after analysis of artificial mouse urine mixture. The multiplet
abbreviations are as follows: s is singlet, d is doublet, t is triplet, dd is doublet of doublets, m is
multiplet, qd is quartet of doublets, dq is doublet of quartets. The concentrations given are in mM
units are calculated based on the number of active nuclei (1H) and the absolute integral of the
peak. This demonstrates that quantitation of this simple mixture is possible. The table is
organized by position of peaks in spectrum.
Multiplet name
HBA 1(d)
Serotonin 1(d)
HIAA 1(s)
Serotonin 2(s)
HPAA 1(m)
Tyrosine 1(s)
Serotonin 3(d)
HIAA 2(d)
HBA 2(d)
HVA 1(s)
Dopamine 1(d)
Dopamine 2(m)
Serotonin 4(d)
HIAA 3(dd)
HVA 2(dd)
Dopamine 3(dd)
Creatinine 1(s)
Tyrosine 2(q)
HVA 3(d)
HPAA 2(s)
HVA 4(d)
Serotonin 5(t)
Dopamine 4(t)
Tyrosine 3(d)
Serotonin 6(t)
Creatinine 2(s)
Dopamine 5(t)
DSS(s)
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Number of
nuclei
2
1
1
1
2
2
1
1
2
1
1
0
1
1
1
2
2
0
3
2
2
1
2
2
2
3
2
15

Range

Absolute Integral

Concentration

7.82..7.75
7.44..7.38
7.38..7.34
7.30..7.25
7.23..7.18
7.18..7.14
7.10..7.06
7.04..7.00
6.96..6.92
6.93..6.91
6.91..6.89
6.86..6.84
6.84..6.83
6.82..6.79
6.78..6.77
6.77..6.72
4.06..4.01
3.96..3.90
3.88..3.82
3.59..3.54
3.54..3.50
3.33..3.26
3.24..3.19
3.19..3.16
3.13..3.07
3.04..3.00
2.88..2.83
0.13..-0.13

16686.3343
8966.7962
8417.6389
9609.9727
22586.7908
13384.7915
9945.7224
8550.9492
11221.8542
11837.2829
19772.8013
9819.9811
8752.1965
9764.9306
5059.4984
13408.3978
5792.9323
1668.7055
13710.2343
8416.7623
7880.357
11328.015
12397.4591
2444.5327
12494.2928
19917.2423
14715.2668
250037.0192

0.3145
0.338
0.3173
0.3622
0.4256
0.2522
0.3749
0.3223
0.2115
0.4461
0.7452
0
0.3299
0.368
0.1907
0.2527
0.1092
0
0.1722
0.1586
0.1485
0.427
0.2336
0.0461
0.2355
0.2502
0.2773
0.6283

Figure 18. Quantitation of artificial mouse urine as a model for quantitation in mouse urine.
Non-overlapping peaks of interest were established for components and concentrations
calculated.
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Figure 19. Comparison of artificial mouse urine mixture and mouse urine sample.
Though there are similarities, further work is necessary to refine the components of the artificial
mixture and adjust the pH. The artificial mixture contains only aromatic compounds, while urine
contains many different compounds which alter the chemical environment and therefore the
spectrum. Higher concentrations of some components in the urine could result in shielding
effects which shift the peak positions. This was evaluated by taking NMR spectra of the artificial
mouse urine at varying concentrations of a single component. While little change was observed
for some components, such as 2-hydroxyindole-3-acetic acid, others showed significant
influence on chemical shift, an example being dopamine as shown in Figure 20.
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Figure 20. 1H NMR spectra of artificial mouse urine spiked with variable concentrations of 2hydroxyindole-3-acetic acid, with increasing concentrations from the top spectrum to the lowest
spectrum. Very little, if any, change in shift was observed.
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Figure 21. 1H NMR spectra of artificial mouse urine spiked with variable concentrations of
dopamine, with increasing concentrations from the top spectrum to the lowest spectrum. A
significant downfield shift of relevant peaks was observed within the spectrum.

Chapter 4: Proposed Protocol for Evaluating Complex Mixtures
Initially, it was naively assumed that pure compounds would have the same chemical shift as in a
mixture containing other NMR-active species. To verify this assumption, a mixture of “artificial
mouse urine” was prepared and evaluated. It was concluded from this that interactions between
compounds in the mixture result in shifts as compared with the standards, which must be accounted
for. Despite this, a large enough number of discrete peaks for each compound were present that
quantitation was possible. The next step was comparing the artificial mouse urine mixture with
real mouse urine to determine if the protocol could work for the sample of interest. The result was
that though quantitation was possible on some of the peaks, it was not accurate to be useful. This
was since too many other compounds were present in the mixture which caused peak overlap and
shift, and additionally differing concentrations and the influence of pH changed the spectrum
sufficiently that not all components were visualized or quantifiable. Continued work needs to be
done to further our understanding of the influence pH on chemical shift and to produce a standard
which is more like the specimen for better quantitation, to evaluate the mixture with LC-MS and
MS-MS for further determination of species present, and to perform COSY or HSQC to delineate
overlapping peaks.

Eason 22

The proposed protocol for mixture analysis in metabolomics involves the development of a
compositionally similar simple mixture on which to calibrate the components of the complex
mixture of interest, such as urine. The analysis of NMR spectra of simple or small mixtures using
MestReNova Simple Mixture Analysis (SMA) is a procedure in part taken from and refined based
on the most recently released version of Mestrelab, which was used in the research (MestReNova
Mestrelab Research Chemistry Software Solutions © Mestrelab Research S.L. Released: 2018-0103 Version: 12.0.1-20560).
The NMR (H)PRESAT experimental spectra of individual mixture components are loaded into the
Mestrelab software for processing of individual compounds which will be standards in the
metabolomics library. Processing involves establishing that the drift correction is 5%, DSS is the
reference compound included in the mixture and set to 0 ppm, the spectrum is zoomed to the
relevant region of the spectrum, the water signal at 4.77-4.78 ppm is suppressed, the spectrum is
manually phased to zero the baseline, the auto baseline correction is applied using the full auto
Whittaker smoother, the protons assigned to individual peaks based on chemical structure, and the
spectrum added to the quantitative simple mixture analysis library. After this, the mixture is edited
to add the new compound and the name of the compound, type (reference or experimental),
molecular weight, “peaks” chosen as the integration method. The formula is taken from the current
spectrum and the relative peak areas ratio checked with verbose pattern recognition.
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Appendices
Appendix A: NMR Spectra
1D Nuclear Magnetic Resonance Spectra

Figure 22. One-dimensional 1H NMR spectrum of tyrosine after manual processing and
automatic peak assignment. Peaks of interest: 7.18 ppm (d), 6.89 ppm (d), 3.93 ppm (q), and 3.11
ppm (qd).
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Figure 23. One-dimensional 1H NMR spectrum of homovanillic acid with manual processing
and automatic peak assignment. Peaks of interest: 6.95 ppm (d), 6.88 ppm (dd), 6.78 ppm (dd),
3.86 ppm (d), and 3.53 ppm (d).
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Figure 24. One-dimensional 1H NMR spectrum of creatinine with manual processing and
automatic peak assignment. Peaks of interest: 4.04 ppm (s) and 3.03 ppm (s).
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Figure 25. One-dimensional 1H NMR spectrum of 5-hydroxyindole-3-acetic acid with manual
processing and automatic peak assignment. Peaks of interest: 7.37 ppm (d), 7.03 ppm (d), 6.82
ppm (dd), and 3.63 ppm (s).
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Figure 26. One-dimensional 1H NMR spectrum of dopamine with manual processing and
automatic peak assignment. Peaks of interest: 6.89 ppm (d), 6.84 ppm (d), 6.74 ppm (dd), 3.22
ppm (t), and 2.86 ppm (t).
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Figure 27. One-dimensional 1H NMR spectrum of 2-hydroxyphenyl acetic acid with manual
processing and automatic peak assignment. Peaks of interest: 7.21 ppm (m), 6.93 ppm (m), 3.59
ppm (s).
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Figure 28. One-dimensional 1H NMR spectrum of serotonin with manual processing and
automatic peak assignment. Peaks of interest: 7.41 ppm (d), 7.28 ppm (s), 7.09 ppm (d), 6.86
ppm (dd), 3.30 ppm (t), and 3.10 ppm (t).
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Figure 29. One-dimensional 1H NMR spectrum of 4-hydroxybenzoic acid with manual
processing and automatic peak assignment. Peaks of interest: 7.86 ppm (m) and 6.93 ppm (m).
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Figure 30. Stacked individual artificial mouse urine (H)PRESAT NMR spectra for evaluation of
chemical shift and peak assignment, showing 6.70 to 7.90 ppm range.
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Figure 31. Stacked individual artificial mouse urine (H)PRESAT NMR spectra for evaluation of
chemical shift and peak assignment, showing 2.75 to 4.10 ppm range.
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Figure 32. Evaluation of shifts of individual (H)PRESAT NMR simple mixture component
spectra and (H)PRESAT NMR artificial mouse urine spectrum.
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Figure 33. Evaluation of shifts of peaks observed in (H)PRESAT NMR spectrum of mouse urine
compared with (H)PRESAT NMR artificial mouse urine spectrum. Quantitative analysis in this
region of the spectrum I only possible at high concentrations as there is overlap with sugars,
amino acids, and other metabolites in this region of the spectrum.

Appendix B: Tables
Table 2. Structures and molecular weights of Mixture A: artificial mouse brain tissue
components. All molecular weights are taken from PubChem and are the monoisotopic masses
listed. For NMR, a Sodium Phosphate buffer was used. The buffer was prepared by combining
1.14 g monosodium phosphate and 2.82 g disodium phosphate in one liter of deionized H2O
achieving a concentration of approximately 2 mmol at pH 7. For LC-MS measurements, a 1:1
methanol buffer was used. All structures created using ChemSketch® free molecular modeling
software.
Sample
Number
40

Name
(Abbreviation)
Tyrosine (Y)

Structure

Molecular Weight (Da)

O

181.073898
OH

NH2

HO

42

O

Glutamate (E)

O

HO

OH
NH2
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145.038605

43

H
N

Tryptophan (W)

204.089874
NH2
O
HO

46

O

Phenylalanine
(F)

165.078979
OH

NH2

53

O

Glycine (G)

75.032028
OH

NH2

75

Dopamine (DA)

76

DLNorepinephrine
(NEE)
Tyramine (pTA)
Serotonin (5Hydroxytryptam
ine) (5-HT)

HO

NH2

153.078979

HO

78
81

HO

HO

NH2
OH
NH2

137.084061

HO

H
N

176.094955
NH2

HO
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169.073898

Table 3. Structures and molecular weights of Mixture B: artificial mouse urine components. All
molecular weights are taken from PubChem and are the monoisotopic masses listed. For NMR, a
Sodium Phosphate buffer was used. The buffer was prepared by combining 1.14 g monosodium
phosphate and 2.82 g disodium phosphate in 1 L of deionized H2O achieving a concentration of
approximately 2 mmol and pH 7. For LC-MS measurements, a 1:1 methanol buffer was used. All
structures created using ChemSketch® free molecular modeling software.
Sample
Number
40

Name
(Abbreviation)
Tyrosine (Y)

Structure

Molecular Weight (Da)

O

181.073898
OH

NH2

HO

60

Homovanillic acid
(HVA)

O

OH

H3C

182.057907

O
HO

61

O

4-Hydroxybenzoic
acid (4-HBA)

138.031693
OH

HO

64

65

OH

2Hydroxyphenylacetic
acid (2-HPAA)
5-Hydroxyindole-3acetic acid (5-HIAA)

152.047348

O
OH
H
N

191.058243

HO

O
OH

75

Dopamine (DA)

77

Creatinine (CR)

HO

NH2

153.078979

HO

H2N

113.058914

N
N

O

H3C

81

H
N

Serotonin (5Hydroxytryptamine)
(5-HT)

NH2
HO
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176.094955

Table 4. Compounds prepared and diluted in series for LC-MS analysis. For every compound,
an initial concentration of approximately 500 μg/ml (±10 μg) was prepared in 20 ml of a 1:1
methanol: deionized H2O buffer. This solution was diluted by half thirteen times, though only
the first eight dilutions were used for LC-MS experiments (500 μg/ml, 250 μg/ml, 125 μg/ml,
62.5 μg/ml, 31.25 μg/ml, 15.63 μg/ml, 7.81 μg/ml, and 3.91 μg/ml). All structures created using
ChemSketch® free molecular modeling software. Some experiments were run using 80%
methanol and 20% deionized H2O with 2 mmol ammonium acetate as solvent (O. Y. AlDirbashi).
Name
(Abbreviation)
Glutamate (E)

Structure
O

O

HO

Mass Used (mg)

Molecular Weight (Da)

10.1

145.038605

9.9

153.078979

10.0

165.078979

10.2

176.094955

10.1

75.032028

10.9

183.089539

10.1

204.089874

10.2

113.058914

10.8

181.073898

10.0

158

OH
NH2

HO

Dopamine (DA)

NH2

HO
O

Phenylalanine
(F)

OH
NH2

H
N

Serotonin (5-HT)

NH2
HO

O

Glycine (G)

OH
NH2

Normetanephrin
e (NME)

OH
O

NH2

H3C
HO

H
N

Tryptophan (W)

NH2
O
HO

H2N

Creatinine (CR)

N
O

N
H3C

O

Tyrosine (Y)

OH
NH2

HO

Dioxoheptanoic
acid (DHA)

O
CH3
HO
O
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O

OH

2Hydroxyphenyla
cetic acid (2HPAA)
Tyramine (p-TA)

O

10.4

152.047348

10.0

137.084061

9.9

138.031693

10.1

191.058243

10.5

182.057907

OH

NH2

HO

O

4Hydroxybenzoic
acid (4-HBA)

OH
HO

5Hydroxyindole3-acetic acid (5HIAA)
Homovanillic
acid (HVA)
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H
N

HO

O

O

OH
OH

H3C
O
HO
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